Last reviewed · How we verify
ADS-8902
ADS-8902 is a Small molecule drug developed by Adamas Pharmaceuticals, Inc.. It is currently in Phase 2 development. Also known as: Amantadine Hydrochloride, Rebetol®, Tamiflu®.
ADAMS-8902's mechanism of action is currently under investigation and not fully characterized.
At a glance
| Generic name | ADS-8902 |
|---|---|
| Also known as | Amantadine Hydrochloride, Rebetol®, Tamiflu® |
| Sponsor | Adamas Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism by which ADAMS-8902 exerts its effects is not yet fully understood, as it is still in the early stages of clinical development.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADS-8902 CI brief — competitive landscape report
- ADS-8902 updates RSS · CI watch RSS
- Adamas Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ADS-8902
What is ADS-8902?
How does ADS-8902 work?
Who makes ADS-8902?
Is ADS-8902 also known as anything else?
What development phase is ADS-8902 in?
Related
- Manufacturer: Adamas Pharmaceuticals, Inc. — full pipeline
- Also known as: Amantadine Hydrochloride, Rebetol®, Tamiflu®